Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Study of CTS-1027 in Hepatitis C Patients


A Dose Response Study of CTS-1027 in Hepatitis C Patients




The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Study Status: Completed


Condition Intervention Phase
Chronic Hepatitis C Virus Infection Drug: CTS-1027
Other: Placebo
Phase 2

Verified by Conatus Pharmaceuticals Inc. September, 2010

Sponsored by: Conatus Pharmaceuticals Inc.
Information provided by: Conatus Pharmaceuticals Inc. identifier: NCT00570336

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

William Frank, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site